Research shows asthma and multi-food allergies elevate the odds of reactions in oral food challenges, emphasizing the importance of careful patient selection.

Click on the article title to read more.

Investing.com -- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced positive results from two Phase 3 trials evaluating first-in-class antibody-blockers targeting cat and birch allergies. The pharmaceutical company reported that both trials successfully met their primary and secondary endpoints. The combination therapy was well-tolerated with no serious adverse events reported during the studies. Following these encouraging results, Regeneron plans to advance its allergy pipeline with additional Phase 3 development scheduled to begin in the first half of 2026. The trials represent progress in Regeneron’s efforts to develop novel treatments for common allergies using antibody-blocking technology, potentially offering new options for allergy sufferers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Is REGN part of an AI-powered winning strategy? ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Nature Communications - Peanut oral immunotherapy (POIT) can treat peanut allergy, but only a subset of patients achieve lasting remission. Here, the authors show that POIT efficacy is associated...

Mice experienced far fewer hay fever symptoms when a pollen-blocking antibody was applied within their nose

Click on the article title to read more.

Click on the article title to read more.

Find out more about the award!

New research identifies a pro-allergic immune cell more common in urban babies — and may hold the key to preventing childhood allergies.

Discover key trends, market size, growth drivers, and forecasts for the Global Cow Milk Protein Allergy Market in 2025. Stay ahead with expert insights.

Peanut allergy could plummet by 77 percent if peanut products were added to all babies’ diets at four to six months of age, according to new research led by the University of Southampton, Kings College London, and the National Institute for Health and Care Research (NIHR).

First clinical trial of its kind could be ‘life changing’ for those living in fear of severe peanut reaction Adults with severe peanut allergies can be desensitised by daily exposure, according to...